ERBB2 and gastric cancer: Different studies provided evidence that protein overexpression and/or gene amplificationof human epidermal receptor-2 (HER2) occurs in solid tumors, including breast and gastric cancer, enabling the therapeutic use of anti-HER2 mAbs or HER2 kinase inhibitors [18,19] in these tumor types.